Search research articles
Contact Us
Filters
Showing results (21-30 of 71) with videos related to
Page
of 8
Sort By:
Cancer Chemotherapy and Biological Response Modifiers
|
April 22, 2003
Tubulin-targeting agents
William N Hait, Eric Rubin, Susan Goodin
Cancer Chemotherapy and Biological Response Modifiers
|
September 2, 2004
Tubulin-targeting agents
William N Hait, Eric Rubin, Susan Goodin
Cancer Chemotherapy and Biological Response Modifiers
|
August 23, 2005
Tubulin-targeting agents
William N Hait, Eric Rubin, Susan Goodin
The Oncologist
|
August 20, 2002
State-of-the-art treatment of metastatic hormone-refractory prostate cancer
Susan Goodin, Kamakshi V Rao, Robert S DiPaola
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 15, 2004
Epothilones: mechanism of action and biologic activity
Susan Goodin, Michael P Kane, Eric H Rubin
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 28, 2012
Abiraterone in prostate cancer: a new angle to an old problem
Mark N Stein, Susan Goodin, Robert S Dipaola
Critical Reviews in Oncology/Hematology
|
May 14, 2005
Drug-drug interactions in oncology: why are they important and can they be minimized?
Peter Blower, Ronald de Wit, Susan Goodin, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
|
May 1, 2007
Current issues associated with oral chemotherapy: a roundtable discussion
Susan Goodin, Joseph Aisner, Sylvia B Bartel, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
|
December 6, 2015
Safety and tolerability of eribulin mesylate in patients with pretreated metastatic breast cancer
Susan Goodin, Sally Barbour, James Song, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 15, 2004
Phase I trial of weekly docetaxel with concurrent three-dimensional conformal radiation therapy in the treatment of unfavorable localized adenocarcinoma of the prostate
Parvesh Kumar, Michael Perrotti, Robert Weiss, et al.
Page
of 8
Search research articles
Search
Showing results (21-30 of 71) with videos related to
Sort By:
Page
of 8
Cancer Chemotherapy and Biological Response Modifiers
|
April 22, 2003
Tubulin-targeting agents
William N Hait, Eric Rubin, Susan Goodin
Cancer Chemotherapy and Biological Response Modifiers
|
September 2, 2004
Tubulin-targeting agents
William N Hait, Eric Rubin, Susan Goodin
Cancer Chemotherapy and Biological Response Modifiers
|
August 23, 2005
Tubulin-targeting agents
William N Hait, Eric Rubin, Susan Goodin
The Oncologist
|
August 20, 2002
State-of-the-art treatment of metastatic hormone-refractory prostate cancer
Susan Goodin, Kamakshi V Rao, Robert S DiPaola
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 15, 2004
Epothilones: mechanism of action and biologic activity
Susan Goodin, Michael P Kane, Eric H Rubin
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 28, 2012
Abiraterone in prostate cancer: a new angle to an old problem
Mark N Stein, Susan Goodin, Robert S Dipaola
Critical Reviews in Oncology/Hematology
|
May 14, 2005
Drug-drug interactions in oncology: why are they important and can they be minimized?
Peter Blower, Ronald de Wit, Susan Goodin, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
|
May 1, 2007
Current issues associated with oral chemotherapy: a roundtable discussion
Susan Goodin, Joseph Aisner, Sylvia B Bartel, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
|
December 6, 2015
Safety and tolerability of eribulin mesylate in patients with pretreated metastatic breast cancer
Susan Goodin, Sally Barbour, James Song, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 15, 2004
Phase I trial of weekly docetaxel with concurrent three-dimensional conformal radiation therapy in the treatment of unfavorable localized adenocarcinoma of the prostate
Parvesh Kumar, Michael Perrotti, Robert Weiss, et al.
Page
of 8